Global Dopamine Agonist Market Size & Outlook, 2025-2030
Global dopamine agonist market, 2018-2030 (US$M)
Related Markets
Global dopamine agonist market highlights
- The global dopamine agonist market generated a revenue of USD 1,314.0 million in 2024 and is expected to reach USD 1,832.5 million by 2030.
- The market is expected to grow at a CAGR (2025 - 2030) of 5.7% by 2030.
- In terms of segment, non-ergot dopamine agonists accounted for a revenue of USD 878.9 million in 2024.
- Non-Ergot Dopamine Agonists is the most lucrative drug segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2024.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2030.
Global data book summary
| Market revenue in 2024 | USD 1,314.0 million |
| Market revenue in 2030 | USD 1,832.5 million |
| Growth rate | 5.7% (CAGR from 2025 to 2030) |
| Largest segment | Non-ergot dopamine agonists |
| Fastest growing segment | Non-Ergot Dopamine Agonists |
| Historical data covered | 2018 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Non-Ergot Dopamine Agonists, Ergot Alkaloids |
Other key industry trends
- In terms of revenue, the North America accounted for 38.0% of the global dopamine agonist market in 2024.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, UK is the fastest growing regional market and is projected to reach USD 117.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Dopamine Agonist Market Scope
Dopamine Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| VeroScience | View profile | 11-50 | Tiverton, Devon, United Kingdom, Europe | http://veroscience.com/ |
| Pfizer Inc. | View profile | - | - | - |
| Union Chimique Belge | View profile | 5001-10000 | Brussels, Brussels Hoofdstedelijk Gewest, Belgium, Europe | http://www.ucb.com |
| Amneal Pharmaceuticals | View profile | 5001-10000 | Bridgewater, New Jersey, United States, North America | http://amneal.com/ |
| Supernus Pharmaceuticals Inc | View profile | 652 | 9715 Key West Avenue, Rockville, MD, United States, 20850 | https://www.supernus.com |
| H. Lundbeck AS Class A | View profile | 5700 | Ottiliavej 9, Valby, Denmark, 2500 | https://www.lundbeck.com |
| Boehringer Ingelheim Pharma | View profile | 10001+ | Dortmund, Nordrhein-Westfalen, Germany, Europe | https://www.boehringer-ingelheim.de/unternehmensprofil/unser-unternehmen/standort-dortmund |
| GSK PLC ADR | View profile | 70200 | 980 Great West Road, Brentford, Middlesex, United Kingdom, TW8 9GS | https://www.gsk.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Global dopamine agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to dopamine agonist market will help companies and investors design strategic landscapes.
Non-ergot dopamine agonists was the largest segment with a revenue share of 66.89% in 2024. Horizon Databook has segmented the Global dopamine agonist market based on non-ergot dopamine agonists, ergot alkaloids covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Dopamine Agonist Drug Outlook (Revenue, USD Million, 2018-2030)
- Non-Ergot Dopamine Agonists
- Ergot Alkaloids
- Global Dopamine Agonist Indication Outlook (Revenue, USD Million, 2018-2030)
- Parkinson's Disease
- Others
- Restless Legs Syndrome (RLS)
- Hyperprolactinemia
- Global Dopamine Agonist Route of Administration Outlook (Revenue, USD Million, 2018-2030)
- Injectable
- Others
- Oral
- Global Dopamine Agonist Distribution Channel Outlook (Revenue, USD Million, 2018-2030)
- Hospital Pharmacies
- Retail Pharmacies
- Other Pharmacies
Reasons to subscribe to Global dopamine agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global dopamine agonist market databook
-
Our clientele includes a mix of dopamine agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global dopamine agonist market , including forecasts for subscribers. This global databook contains high-level insights into Global dopamine agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global dopamine agonist market size, by regions, 2018-2030 (US$M)
Top 10 countries: Dopamine agonist market size, 2024 (US$M)
Global dopamine agonist market share, by drug, 2024 & 2030 (%, US$M)
Dopamine agonist market: Opportunity assessment by country
Global dopamine agonist market, by region, 2024 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
